NDAORALCAPSULEPriority Review
Approved
Feb 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ATROMID-S (clofibrate) is an oral fibrate medication approved in 1967 for managing dyslipidemia and related lipid disorders. It works by activating peroxisome proliferator-activated receptors (PPARs) to modulate lipid metabolism and reduce triglycerides and cholesterol. This is a legacy small-molecule therapeutic with decades of clinical use.
LOE Approaching
As LOE approaches, the brand team is likely in defensive/maintenance mode with smaller commercial footprint and reduced investment in field expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ATROMID-S offers limited career growth given its LOE-approaching status and minimal linked job openings. This role suits professionals seeking legacy product management, regulatory maintenance, or market access experience in a stable but declining portfolio.
Regulatory Affairs SpecialistProduct Manager (Legacy)
Worked on ATROMID-S at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.